A Phase 2 interventional study of Memantine Hydrochloride (HCl) in Autism Spectrum Disorder (ASD), Autism and Autistic Disorder, sponsored by Forest Laboratories. Completed at 118 sites in 18 countries. Open to participants aged 6 Years to 12 Years. Per ClinicalTrials.gov, last updated 2014-08-07.
Sponsored by Forest Laboratories (part of AbbVie) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 773 studies in Autism Spectrum Disorder with a site in United States — 165 open to participants now, 204 under way, 9 of them phase 3. Autism Spectrum Disorder · United States.
Among the 773 studies in Autism Spectrum Disorder with a site in United States, this one is the 7th largest by enrollment of the 658 interventional ones that give a count, is one of 26 that started in 2012, is one of 101 in phase 2, and was the 89th registered.
1,728 studies on the registry are indexed under Autism Spectrum Disorder; 501 are open to participants now.
Browse Autism Spectrum Disorder studies →165 of the 773 studies in Autism Spectrum Disorder with a site in United States are open now. Recruiting first, the newest first:
New York State Institute for Basic Research · Sites in United States
Ages 5–12
Massachusetts General Hospital · Sites in United States
Ages 12–17
Schweitzer Engineering Laboratories · Sites in United States
Ages 24 mo–60 mo · Healthy volunteers
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 12–18
Bristol-Myers Squibb · Sites in United States, Australia, Canada and 1 more country
Ages 5–17
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 350 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 295 (84%) stop at 75 or younger; 299 take children under 18; 92 take healthy volunteers.
This study: 6 Years to 12 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
773 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 52 · Phase 2 117 · Phase 3 33 · Phase 4 16
First in 2004; this study’s year is marked. 26 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 906 is above the median of 51 across 1,371 interventional studies indexed under Autism Spectrum Disorder.
Median enrollment 50 across the 658 interventional studies, 132 across the 114 observational. Of the 522 that completed or were terminated, 174 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
89 of 773 have an industry lead sponsor. The 10 most frequent:
This study is registered under Forest Laboratories, one of the names counted as AbbVie. Under that name alone:
Forest Laboratories is the lead sponsor of 168 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
AbbVie has 6 studies filed under Autism Spectrum Disorder — fewer than ten, so there is no comparison to draw.
67 of the studies in Autism Spectrum Disorder with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06706674Phase 3Intra-Cellular Therapies, Inc.Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients | 2027-06-21 |
| NCT06690398Phase 3Intra-Cellular Therapies, Inc.Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric Patients | 2027-06-21 |
| NCT07670000Natalia PoluektovaMental And Speech Developmental Delay Autism Spectrum-Type Behavioral Disorder | 2026-11 |
| NCT04242355Yale UniversityTranscranial Magnetic Stimulation on Neural and Behavioral Facets of Social Cognition in Autism Spectrum Disorder | 2026-12 |
| NCT06059352Loma Linda UniversitySleep and Central Auditory Processing Disorder in Autism Spectrum Disorder | 2026-12 |
Add all 67 to your calendar (.ics) → With an account.
Among the 773 studies in Autism Spectrum Disorder with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and tolerability of memantine in pediatric (6-12 years old) patients with autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) and to identify responders for participation in a follow-up randomized withdrawal study.
This 50-week multicenter and multinational clinical study is comprised of a 2-week screening period, a 6-week open-label dose-titration period followed by a variable duration maintenance period (up to 42 weeks).
Patients with at least 12 weeks of investigational product exposure who meet the protocol specified responder criterion at two consecutive visits separated by at least two weeks are eligible to transition to a randomized withdrawal study. A responder is defined as a patient who demonstrates at least a 10 point improvement (reduction in score) in the Social Responsiveness Scale (SRS) total raw score relative to the Visit 1 total raw score.
Weight based dose limits were selected in this study to ensure that exposure in terms of area under the curve (AUC) was less than the predefined limit of 2100 ng·h/mL which represents a 10-fold lower exposure than observed at the No observed adverse effect level (NOAEL) of 15 mg/kg/day in juvenile rats.
The weight-based dose limits in this study were as follows:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Once daily oral administration of open-label memantine for up to 48 weeks: 6-week dose-titration period followed by up to 42-week maintenance period.
Drug: Memantine Hydrochloride (HCl)
Memantine extended release 3-mg capsules; the dosages studied ranged from 3 - 15 mg/day; weight based dosing in 4 weight groups; oral administration. Dosing is once daily for up to 48 weeks.
Also known as: Namenda
Number of Confirmed Social Responsiveness Scale (SRS) Responders
A confirmed SRS responder was defined as a patient who had at least 12 weeks of exposure to memantine, and a ≥ 10-point reduction in the SRS total raw score relative to baseline at 2 consecutive visits separated by at least 2 weeks. The SRS is a 65-item, caregiver-rated assessment scale that measures observable items on social behavior and social language use, as well as characteristics of autism in a naturalistic social setting. Each item is rated on a scale from 0 (never true) to 3 (almost always true). The SRS total raw score ranges from 0 to 195; a higher score indicates greater severity of social impairment.
Time frame: Visit 1 (Baseline) to Visit 8 (week 48/Final Visit)
Patient recruitment occurred over an eleven month period, from June of 2012 to May of 2013, at 118 study sites, located in the United States and 17 other countries.
| Milestone | Memantine Hydrochloride (HCl) |
|---|---|
| Started | 903 |
| Completed | 765 |
| Not completed | 138 |
| Withdrew: Adverse event | 60 |
| Withdrew: Lack of efficacy | 19 |
| Withdrew: Protocol violation | 14 |
| Withdrew: Withdrawal by subject | 23 |
| Withdrew: Lost to follow-up | 19 |
| Withdrew: Other | 3 |
A confirmed SRS responder was defined as a patient who had at least 12 weeks of exposure to memantine, and a ≥ 10-point reduction in the SRS total raw score relative to baseline at 2 consecutive visits separated by at least 2 weeks. The SRS is a 65-item, caregiver-rated assessment scale that measures observable items on social behavior and social language use, as well as characteristics of autism in a naturalistic social setting. Each item is rated on a scale from 0 (never true) to 3 (almost always true). The SRS total raw score ranges from 0 to 195; a higher score indicates greater severity of social impairment.
| participants | Memantine Hydrochloride (HCl) |
|---|---|
| Responders | 517 |
| Non responders | 351 |
Collected over Adverse event data was collected over a 14 month period from June 2012 to August 2013 at 118 study sites in the US and 17 other countries.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Memantine Hydrochloride (HCl) | — | 6/903 (0.7%) | 196/903 (21.7%) |
| Event | Memantine Hydrochloride (HCl) |
|---|---|
| Abnormal behaviourPsychiatric disorders | 2/903 |
| Accidental exposureInjury, poisoning and procedural complications | 1/903 |
| ConstipationGastrointestinal disorders | 1/903 |
| DisinhibitionPsychiatric disorders | 1/903 |
| GastroenteritisGastrointestinal disorders | 1/903 |
| Event | Memantine Hydrochloride (HCl) |
|---|---|
| HeadacheNervous system disorders | 72/903 |
| NasopharyngitisInfections and infestations | 57/903 |
| PyrexiaGeneral disorders | 52/903 |
| IrritabilityGeneral disorders | 49/903 |
A total of 906 patients were enrolled in the open-label study. Of these, 903 patients received at least 1 dose of open-label treatment to comprise the Safety Population. 868 patients in the Safety Population also had at least 1 post-Visit 1 assessment of the SRS total raw score to comprise the Intent to Treat (ITT) population
| Age, Continuous(Years) | Memantine Hydrochloride (HCl) |
|---|---|
| Mean | 9.0 ± 1.9 |
| Sex/Gender, Customized(participants) | Memantine Hydrochloride (HCl) |
|---|---|
| Male | 759 |
| Female | 144 |
| Race/Ethnicity, Customized(participants) | Memantine Hydrochloride (HCl) |
|---|---|
| White | 768 |
| Black or African American | 54 |
| Asian | 54 |
| American Indian or Alaska Native | 2 |
| Native Hawaiian or Other Pacific Islander | 3 |
| Other | 22 |
| Hispanic or Latino | 102 |
| Not Hispanic or Latino | 801 |
| Region of Enrollment(participants) | Memantine Hydrochloride (HCl) |
|---|---|
| United States | 712 |
| Australia | 0 |
| Belgium | 11 |
| Canada | 1 |
| Colombia | 8 |
| Estonia | 6 |
| France | 14 |
| Hungary | 20 |
| Iceland | 5 |
| Italy | 6 |
| Korea, Republic of | 25 |
| New Zealand | 2 |
| Poland | 37 |
| Serbia | 21 |
| Singapore | 0 |
| South Africa | 2 |
| Spain | 17 |
| Ukraine | 16 |
Showing the first 100 of 118 sites across 18 countries. Choose a country and city above to see the rest.
The record gives a start of Jun 2012, a primary completion of Jul 2013 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2014, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Memantine